RBC Capital Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to RBC Capital Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)
June 1, 2024 10:00 AM EDT
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25Â were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses 1.2mg/KgNo dose limiting toxicities (DLTs) have been observed to date in doses up to and including 4.5 mg/Kg (cohort 7)Three cases of skin rash (including one grade 3) and one case of grade 1 neuropathy seen to date; all were... More
May 30, 2024 8:00 AM EDT
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the 45th Annual Goldman Sachs Global Healthcare Conference to be held June 10-13, 2024 in Miami Beach, FL.
45th Annual Goldman Sachs Global Healthcare Conference Format: Presentation and one-on-one investor meetingsPresentation Date: Wednesday, June 12, 2024Presentation Time: 2:40 p.m. ETWebcast:... More
